Artiva Biotherapeutics(NASDAQ) ARTV

Artiva Biotherapeutics develops ready-to-use cell therapies for patients. These treatments help people fighting severe autoimmune diseases and cancer. The company uses donor cells to create accessible medicines for hospitals.

What Artiva Makes

• AlloNK (AB-101): Donor-derived natural killer cell therapy; used in combinations to treat autoimmune diseases like rheumatoid arthritis and Sjögren's disease.
• AB-201: Chimeric antigen receptor (CAR)-NK therapy; engineered to target the HER2 protein found on certain cancer cells.
• AB-205: Experimental immune cell therapy; designed to find and treat cancers that express the CD5 protein.

Recent Growth and Milestones

• Secured Fast Track Designation from the FDA in October 2025 for treating refractory rheumatoid arthritis.
• Received Regenerative Medicine Advanced Therapy (RMAT) designation in June 2026 to speed up the development of its lead therapy.
• Closed a public stock offering in May 2026 that generated $282.7 million in net proceeds.
• Initiated a global Phase 2a clinical trial in August 2025 for patients with various autoimmune conditions.

The Ready-to-Ship Model

Artiva uses an "off-the-shelf" approach that relies on donor cells, meaning treatments are pre-manufactured and frozen for immediate use. This model eliminates the time-consuming process of collecting and modifying a patient's own cells before they can receive therapy.

A Look at the Books

• Net loss was $48.5 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and investments totaled $349.4 million as of June 30, 2026.
• Research and development expenses reached $41.2 million for the six-month period ended June 30, 2026.
• Net proceeds from the May 2026 stock offering were $282.7 million.
• Accumulated deficit grew to $379.1 million as of June 30, 2026.

A Final Look

Artiva has shifted its primary focus from oncology to developing therapies for refractory autoimmune diseases. This strategic pivot leverages its manufacturing platform to address large markets with significant unmet medical needs.